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Albumin-heparin microspheres have been prepared as a new drug carrier. A soluble albumin-heparin 
conjugate was synthesized byforming amide bonds between human serum albumin and heparin. After 
purification the albumin-heparin conjugate was crosslinked in a water-in-oil emulsion to form albumin- 
heparin microspheres. The composition fthe conjugate was determined byamino acid analysis. The 
swelling properties ofalbumin-heparin microspheres were investigated as a function of pH and ionic 
strength and compared with albumin microspheres. Albumin-heparin a d albumin microspheres exhibited 
stimuli-sensitive swelling. Both microsphere systems exhibited low swelling at low pH and high swelling 
at higher pH caused by ionization of amino acids of serum albumin. The swelling of albumin-hepafin 
microspheres was more sensitive toward ionic strength an that of albumin microspheres. This was due 
to the greater negative charge of the albumin-heparin microspheres. Surfaces of albumin-heparin a d 
albumin microspheres were characterized by ESCA, contact angle measurements, electrophoresis, and 
scanning electron microscopy. Surface analysis ndicated the presence ofheparin at the albumin-heparin 
microsphere/water interface. © 1991 Academic Press, Inc. 
INTRODUCTION 
In recent years, polymeric microspheres 
have been ubiquitously investigated as drug 
delivery systems ( 1 ). The interest in polymeric 
microspheres a drug carriers is due to the fact 
that these systems are injectable, can deliver 
drugs site specifically, and can release drugs in 
a controlled manner (2). The delivery of a 
drug, protected by a drug carrier or dosage 
form, to a specific site of action (e.g., tumor 
or specific organ) may increase the therapeutic 
index of that drug (3). 
In this contribution, the preparation of mi- 
crospheres based on conjugates of serum al- 
bumin and heparin that could be used as a 
new drug delivery system is described. Cur- 
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rently there is much interest in the delivery of 
macromolecules, derived through biotechnol- 
ogy, due to their low oral bioavailability and 
short plasma half-lives (3). The viability of 
the microsphere approach has been investi- 
gated by Goosen et al. (4) with albumin mi- 
crospheres for the sustained release of insulin. 
After subcutaneous injection of the insulin- 
loaded microspheres, diabetic rats showed el- 
evated blood insulin levels for up to 2 months. 
Immobilizing heparin in albumin micro- 
spheres may increase its blood and tissue 
compatibility. Many workers have attempted 
to inhibit thrombosis at polymer/blood inter- 
faces by immobilizing heparin to polymer 
surfaces (5). Heparin is a highly negatively 
charged mucopolysaccharide and may en- 
hance the hydrophilicity of albumin micro- 
spheres. Longo and Goldberg (6) have dis- 
cussed the advantages of hydrophilic poly- 
meric microspheres for drug delivery. A study 
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on the release of Adriamycin from albumin- 
heparin microspheres has been previously re- 
ported (7). 
The composition of the albumin-heparin 
conjugate was determined by amino acid 
analysis. The size distribution of microspheres 
was measured. To establish the enhanced hy- 
drophilicity of albumin-heparin microspheres 
the swelling as a function of pH and ionic 
strength of albumin-heparin microspheres in 
aqueous ystems was compared to that of al- 
bumin microspheres. 
The surface characteristics of albumin- 
heparin and albumin microspheres were then 
examined. Surface properties largely deter- 
mine the biocompatibility of microspheres 
when interfaced with body tissues and blood 
and they affect the distribution of intrave- 
nously administered microspheres through the 
process of opsonification (1). Due to their 
small size polymeric microspheres have a large 
specific surface area which would interface 
with the biological milieu. A thorough study 
of the surface characteristics of albumin-hep- 
arin microspheres was necessary to correlate 
in vivo performance with surface properties. 
The surfaces of albumin-heparin a d albumin 
microspheres were therefore characterized by
ESCA, contact angle measurements, electro- 
phoresis, and scanning electron micros- 
copy (SEM). 
MATERIALS AND METHODS 
MATERIALS 
Human serum albumin (lyophilized and 
crystallized), olive oil, and 1-ethyl-3-(3-di- 
methylaminopropyl) carbodiimide (EDC) 
were obtained from Sigma (St. Louis, MO). 
Heparin (lot number LPP060143, average 
molecular weight 11,000), from porcine in- 
testinal mucosa, was obtained from Diosynth 
(Oss, The Netherlands). Purified glutaralde- 
hyde (25%, w/v) was purchased from Fisher 
(Pittsburgh, PA). Sodium cyanoborohydride 
was obtained from Aldrich (Milwaukee, WI). 
Blue Sepharose CL-6B and Diethylaminoethyl 
(DEAE)-Sepharose CL-6B were obtained 
from Pharmacia (Piscataway, NJ). Micro- 
concavity slides were purchased from Clay- 
Adams (Parsipanny, NJ). Pluronic F-68 was 
received from BASF (Parsipanny, NJ). Cel- 
lulose acetate (molecular weight cutoff 1000 
and 3500) dialysis membranes and polytet- 
rafluoroethylene membranes (0.45-#m pore 
size) were obtained from Gelman (Ann Arbor, 
MI). Sodium acetate (0.1 N)/aeetonitrile 
buffer (HPLC grade) was obtained from VWR 
(Philadelphia, PA). Phenyl isothiocyanate was 
obtained from Pierce (Rockford, IL). Latexes 
( 10 and 100 ~m) were purchased from Coulter 
Counter (Hialeah, FL). All other chemicals 
were reagent grade. 
METHODS 
Synthesis of Albumin-Heparin Conjugate 
The protocol used to synthesize the soluble 
albumin-heparin conjugate was based on the 
method of Hennink et al. (8). The procedure 
was slightly modified to inhibit denaturation 
of the serum albumin. A buffer was used to 
keep the pH constant during the course of the 
reaction without he addition of HC1, and all 
steps were carried out at 4°C. Heparin (770 
mg) and serum albumin (2590 mg) were dis- 
solved in 39.0 ml phosphate buffer (0.061 M 
monopotassium phosphate, 5.33 X 10 -4 M 
disodium phosphate), pH 5.10. The solution 
was adjusted to pH 5.10 with 0.10 M HC1. 
Then, 32.5 mg EDC was dissolved in 1.00 ml 
distilled water and added to the heparin and 
serum albumin solution. This was repeated 
seven more times at 30-min intervals. The to- 
tal amount of EDC added was 260 mg. The 
pH was adjusted to pH 7.00 with 1.00 M 
NaOH 30 min after the last addition of EDC. 
The resultant solution was then gently stirred 
for 20 h. The solution was dialyzed (cellulose 
acetate, 1000 molecular weight cutoff) twice 
against 0.17 M NaCI, 0.025 M Tris/HC1, pH 
7.00, for 6 h. 
The albumin-heparin conjugate was puri- 
fied from free serum albumin and heparin us- 
ing a two-step liquid chromatography proce- 
dure. Heparin was removed by using a Blue 
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Sepharose CL-6B column. The column was 
first equilibrated with two bed volumes of 0.17 
M NaC1, 0.025 M Tris/HC1, pH 7.40, buffer. 
A mixture of albumin-heparin conjugate and 
unbound heparin and serum albumin dis- 
solved in 0.17 MNaC1, 0.025 MTris/Hcl, pH 
7.40, buffer was applied to the column, and 
the heparin was eluted with one column vol- 
ume of starting buffer. The albumin-heparin 
conjugate and serum albumin were eluted by 
a stepwise ionic strength gradient of 1.5 M 
NaC1, 0.025 M Tris/HC1, pH 7.40, buffer. 
Heparin was determined by using a toluidine 
blue assay described elsewhere (9). The frac- 
tions were assayed for serum albumin by mea- 
suring the absorbances at280 nm with a UV 
spectrophotometer (UV- 1, Pharmacia, Upp- 
sala, Sweden). Fractions with absorbances 
greater than 0.5 were collected, pooled, and 
dialyzed (cellulose acetate, 3500 molecular 
weight cutoff) three times against 8 liters of 
deionized water. The sample was then freeze- 
dried (Lyph-Lock6, LabConCo, Kansas City, 
MO). The albumin-heparin conjugate and 
serum albumin were then redissolved in 0.30 
MNaC1, 0.025 M Tris/HC1, pH 7.40, buffer 
and applied to the DEAE-Sepharose CL-6B 
column which had been equilibrated with 0.30 
M NaC1, 0.025 M Tris/HC1, pH 7.40, buffer. 
Serum albumin was eluted with one column 
of starting buffer. The albumin-heparin con- 
jugate was eluted by a stepwise ionic strength 
gradient of 0.90 M NaC1, 0.025 M Tris/HC1, 
pH 7.40. The fractions of albumin-heparin 
conjugate that exhibited an absorbance greater 
than 0.5 were collected, pooled, and dialyzed 
against 8 liters of deionized water. The con- 
jugate was then freeze-dried. All separation 
and dialysis procedures were carried out 
at 4°C. 
Preparation of Albumin-Heparin 
and Albumin Microspheres 
Microspheres were synthesized using a pro- 
tocol similar to that of Burger et al. (10). A 
125-ml volume of olive oil was placed in a 
baffled cell (10) and stirred at a predetermined 
rate for 30 min. The 100 mg ofalbumin-hep- 
arin conjugate or serum albumin, which had 
been dissolved in 400 #1 of distilled water at 
4°C, was injected ropwise into stirred olive 
oil at 25°C, and stirring was continued for 15 
rain. A predetermined amount of purified 
glutaraldehyde (25%, w/v) to make 1 to 4% 
(w / v) of the added albumin-heparin solution 
was then added along with twice the equimolar 
amount of sodium cyanoborohydride solu- 
tion. The crosslinking reaction was allowed to 
proceed for 3.5 h. A 100-ml aliquot ofglycine 
(10%, w/v) was then added to quench un- 
reacted aldehyde groups and allowed to pro- 
ceed for 30 min. Subsequently 60 ml of ace- 
tone was added and the emulsion stirred for 
1 rain. The microspheres were isolated by 
centrifugation (MSE, VWR, Philadelphia, 
PA) at 1000 rpm for 15 min. The supernatant 
was then decanted. The microspheres were re- 
suspended in acetone, collected on a 0.45-gm 
polytetrafluoroethylene m mbrane, and 
washed and dehydrated with acetone. The 
collected microspheres were suspended in 
acetone, sieved between appropriate sized mi- 
crosieves (U.S. Standard, Newark Wire Cloth, 
Newark, N J), and washed with isotonic phos- 
phate buffer (PBS) (2.00 × 10-3 Mpotassium 
phosphate, 8.00 X 10 -3 M disodium phos- 
phate, 0.145 M NaC1), pH 7.40, and distilled 
water. The microspheres were air-dried for 24 
h, vacuum-dried for an additional 24 h, and 
stored frozen. Albumin-heparin a d albumin 
gels used for contact angle measurements were 
prepared by in situ crosslinking of the proteins 
in syringes at 4°C. 
Composition 
The composition of the albumin-heparin 
conjugate was determined by amino acid 
analysis. Briefly, the method first involved hy- 
drolysis of the sample. The determinations of 
serum albumin and heparin were carried out 
independently because hydrolysis conditions 
for proteins are too harsh for polysaccharides 
and result in degradation ( 11 ). Hydrolysis of 
serum albumin was carried out with 6 N HC1 
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at 106°C for 20 h. For the analysis ofheparin, 
hydrolysis was done with 4 N HC1 at 100°C 
for 16 h. Subsequently the amino acids and 
glucosamine were derivatized using phenyl 
isothiocyanate to form phenylthiocarbamoyl 
(PTC) derivatives. The PTC derivatives were 
then separated using sodium acetate (0.1 N) / 
acetonitrile buffer as the mobile phase with 
reverse phase column (Ultrasphere OPS, 4.6 
mm × 15 cm, Waters, San Francisco, CA) 
using HPLC ( 1084B, Waters, San Francisco, 
CA). The amount of PTC derivative was de- 
termined by measuring absorbance at254 nm 
with a UV spectrophotometer (484, Waters). 
Heparin standards were analyzed by the same 
procedure. 
Analysis of Size Distribution 
The size distribution of swollen and un- 
swollen albumin-heparin and albumin mi- 
crospheres (n = 300) was determined by 
phase-contrast light microscopy (Biophot, 
Nikon, Tokyo, Japan) using a calibrated grat- 
icule. Calibration was done with latexes of 
known size. 
Swelling 
Equilibrium swelling of microspheres was 
studied as a function ofpH and ionic strength. 
To examine the effects of pH on the swelling 
of albumin-heparin and albumin micro- 
spheres, a universal buffer, Britton and Rob- 
inson (12), was used and the ionic strength of 
the buffer was adjusted to a constant value of 
0.21 with sodium chloride. The effect of ionic 
strength on swelling was examined using an 
isotonic PBS, pH 7.40, with sodium chloride 
added to adjust he ionic strength of the media. 
The swelling was also studied as a function of 
glutaraldehyde used for crosslinking. Equilib- 
rium swelling was determined in isotonic PBS, 
pH 7.40. All swelling experiments were done 
at 25°C. The swelling ratio 
Vswollen q = - -  [1] 
Vdned 
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was determined by measuring the diameter of 
albumin-heparin a d albumin microspheres 
(n = 50) by phase-contrast light microscopy 
(Biophot, Nikon) and by assuming a spherical 
geometry. Albumin-heparin and albumin 
microspheres sieved between 38 and 53 ~,m 
with an average dry diameter of 40 +_ 5 #m 
were used for these studies. Standard error of 
the means (s.e.m.) of the swelling ratio was 
calculated by propagating the error of the mi- 
crosphere diameter ( 13 ). 
Surface Characterization of Albumin- 
Heparin and Albumin Microspheres 
ESCA analysis. The chemical nature of al- 
bumin-heparin and albumin microsphere 
surfaces was studied by ESCA (5950B, Hew- 
lett-Packard, Palo Alto, CA). The X-ray 
source was a monochromatic A1Kal,2 and had 
an energy of 1487 eV and 400 W power at the 
anode. To inhibit charging, an electron flood 
gun bathed the surface of the microspheres at
6.0 eV. Albumin-heparin and albumin mi- 
crospheres were prepared by vacuum-drying. 
Albumin-heparin microspheres were also 
prepared by freeze-drying. Samples were fro- 
zen at -60°C with dry ice in acetone and then 
freeze-dried (Lyph-Lock6, LabConCo). 
Atomic percentages ofeach sample were cal- 
culated by utilizing area sensitivity techni- 
ques (14). 
Contact angle measurements. The contact 
angles of albumin-heparin a d albumin gels 
were determined using a goniometer (A-100, 
Rame-Hart, Inc., Mountain Lakes, N J). 
Droplets of double-distilled water were care- 
fully placed via a syringe onto the surface of 
the gel. The advancing contact angle was de- 
termined by measuring the angle of the tangent 
to the drop with the surface at the gel/water/ 
air meeting point. Measurements were carried 
out at 25°C in triplicate and standard evia- 
tions were calculated. The water contents of 
the gels were determined by measuring the 
weight of the gels swollen in deionized water 
and the weight of the dried gels. The water 
contents (in percent) were defined as the 
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weight of the swollen gel minus the weight of 
the dried gel divided by the weight of the swol- 
len gel. 
Electrophoresis measurements. The zeta 
potentials of albumin-heparin and albumin 
microspheres were measured by electropho- 
resis (3.0, Zetameter Inc., Long Island City, 
NY). The average diameter of the micro- 
spheres was 60 + 27 #m. An isotonic PBS, 
7.40, was used for the determination of zeta 
potentials, and all experiments were done at 
25°C. The zeta potential of albumin micro- 
spheres was determined using 0.1% Pluronic 
F-68, a nonionic surfactant, to prevent floc- 
culation. The Smoluchowski equation was 
used to calculate the zeta potentials, 
g-=#~ [2] 
(assuming KR > 100), where # is defined as 
the electrophoretic mobility. This value is ex- 
perimentally obtained by determining the ve- 
locity of microspheres in an applied electric 
field by light microscopy. Measurements were 
carried out in triplicate and standard evia- 
tions were calculated, n is the viscosity of the 
bulk medium, eeo is the dielectric permittivity 
of the medium. K, the reciprocal of the Debye 
length, is determined by the composition of 
the medium 
e 2 \2 /2  
[3] 
e is the elementary charge, k is the Boltzmann 
constant, T is the absolute temperature, and 
c~ and zi are the concentration and valency of 
the ionic species. R is the radius of albumin- 
heparin microspheres. The Debye length is less 
than 10 ~ under isotonic conditions. 
SEM. The surfaces of albumin-heparin a d 
albumin microspheres were studied using 
SEM. Microspheres were vacuum-dried over- 
night and then placed on stubs and sputter- 
coated with Au/Pd using a sputter coater 
(Hammer III, Technics, Alexandria, VA). The 
surfaces were examined with SEM (JSM-35, 
JEOL, Peabody, MA). 
RESULTS AND DISCUSSION 
To immobilize heparin within an albumin 
matrix, soluble albumin-heparin conjugate 
was first synthesized. Since heparin and serum 
albumin do not interact at physiological con- 
ditions ( 15 ), heparin was covalently bound to 
serum albumin via amide bonds. The carboxyl 
groups of serum albumin and heparin are 
preactivated by EDC in the presence of an ex- 
ternal nucleophile, the lysine residue, and thus 
the formation of the N-acylurea is inhibited 
(16). By using a buffer the pH did not have 
to be adjusted uring the course of the reac- 
tion. The pH did slightly increase with each 
addition of EDC as hydrogen ions were con- 
sumed in the reaction (16). The pH 30 min 
after the last addition of EDC was 5.24. 
Purification of the albumin-heparin con- 
jugate was accomplished with liquid chro- 
matography, and the elution profiles are 
shown in Figs. 1 and 2. Heparin was isocrat- 
ically eluted from the Cibacron Blue F3G-A 
column. When a stepwise ionic strength gra- 
dient was applied a skewed peak was observed. 
This peak represents he serum albumin and 
the albumin-heparin conjugate. The skewed 
peak is due to the difference in affinity between 
the serum albumin and albumin-heparin 
conjugate toward the immobilized ye. It was 
not possible to resolve the two components on 
this column. Serum albumin was eluted iso- 
cratically on the DEAE-Sepharose CL-6B col- 
umn, and using a stepwise ionic strength gra- 
dient the albumin-heparin conjugate was 
eluted from the column (Fig. 2). The greater 
affinity of the albumin-heparin conjugate to- 
ward DEAE-Sepharose CL-6B was a result of 
the greater negative charge associated with the 
albumin-heparin conjugate relative to serum 
albumin. The percentage yield of the albumin- 
heparin conjugate after purification was 30% 
based on the initial weight of the serum al- 
bumin and heparin. 
Albumin-heparin microspheres were pre- 
pared by crosslinking the conjugate in a water- 
in-oil emulsion. The percentage yield of al- 
bumin-heparin and albumin microspheres 
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FIG. 1. Elution profile of heparin, serum albumin, and albumin-heparin conjugate on Blue Sepharose 
CL-6B• Initial buffer: 0.17 M NaC1, 0.025 M Tris/HC1, pH 7.40; B: 1.50 M NaC1, 0.025 M Tfis/HC1, pH 
7.40. Heparin, closed circles; albumin-heparin conjugate and serum albumin, open circles. 
was 90%. Dried microspheres are free-flowing 
light tan powders. Albumin-heparin micro- 
spheres, crosslinked with glutaraldehyde, 
which was not reduced, formed imine bonds 
which may undergo subsequent reactions and 
are brownish in appearance. Imine bonds are 
unstable in aqueous media and thus should 
undergo reduction (17). 
The size of the microspheres may be con- 
trolled by a number of experimental variables: 
oil phase viscosity, oil phase volume, protein 
concentration, aqueous phase volume, and 
stirring rate (10). All variables were kept con- 
stant and the size was altered by varying the 
stirring rate and by sieving• The fate of micro- 
spheres after intravenous injection has been 
shown to be largely dependent on microsphere 
size and has been exploited for the site-specific 
delivery of antineoplastics ( 1, 18 ). Albumin- 
heparin microspheres that were made using a 
stirring rate of 500 rpm had an average di- 
ameter of 60 + 27 um in the swollen form. 
Microspheres were prepared with diameters 
ranging from 1 to 300 #m. 
The composition of the albumin-heparin 
conjugate issummarized in Table 1. The con- 
tent of serum albumin was directly quantified 
by obtaining the number of moles of amino 
3 
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FIG. 2. Elution profile of serum albumin and albumin-heparin conjugate on DEAE Sepharose CL-6B. 
Initial buffer: 0.30 M NaCI, 0.025 M Tris/HC1, pH 7.40; B: 0.90 M NaCI, 0.025 M Tris/HC1, pH 7.40. 
Serum albumin, open circles; albumin-heparin conjugate, closed circles. 
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TABLE I 
Composition of Albumin-Heparin Conjugate 
Heparin content a Albumin content" Albumin/heparin 
[wt %] [wt %] [tool/tool] 
9.54 ± 0.46 90.5 ± 0.30 1.58 _+ 0.07 b 
a Determination by amino acid analysis. 
b SD (n = 3). 
acids. The heparin content was determined by 
quantifying the number of moles of glucos- 
amine. The weight percentage of heparin in 
the albumin-heparin conjugate was found to 
be 9.54% by amino acid analysis. The amount 
of incorporated heparin is quite large relative 
to other similar heparin-immobilized hydrogel 
systems which contain 0.64% by weight hep- 
arin (19). The heparin is expected to be 
bioactive, and a systematic n vitro study of 
the blood compatibility of albumin-heparin 
microspheres is currently in progress. 
Figure 3 shows that pH can act as an exter- 
nal stimulus to modulate the swelling of al- 
bumin-heparin microspheres; the degree of 
swelling is dependent on the crosslink density. 
A hydrogel network which has a higher cross- 
link density exhibits a greater retractive force 
which prevents the gel from expanding (20). 
The swelling changes reflect he ionization of 
functional groups of amino acids (e.g., Asp, 
Glu, and Lys) of serum albumin and carboxyl 
groups of heparin which is dependent on pH. 
An increased number of like negative charges 
associated with the polymer chains result in 
expansion of the chain which is opposed by 
polymer network retractive forces and poly- 
mer-polymer interactions (20, 21 ). In Fig. 4, 
the pH-dependent swelling of albumin-hep- 
arin and albumin microspheres at 1% (w/v) 
glutaraldehyde is shown. The swelling of al- 
bumin microspheres is sensitive toward pH 
and also reflects the ionization of amino acids. 
Counterions in solution may effectively neu- 
tralize the repulsion of like charges along the 
polymer chain through electrostatic interac- 
tion, thus shielding the charge on the polymer 
chain and decreasing swelling (Fig. 5). The 
swelling of albumin-heparin microspheres is 
greater and exhibits more sensitivity toward 
ionic strength than albumin microspheres due 
to the higher negative charge of albumin-hep- 
arin microspheres. The swelling of synthetic 
hydrogels may be altered by the degree of 
crosslinking, and Fig. 6 illustrates that this is 
also possible with albumin-heparin micro- 
spheres. Stimuli-sensitive swelling with syn- 
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FIG. 3. pH-dependent  swell ing o fa lbumin-hepar in  mi-  
crospheres with vary ing crossl inking (%, w/v ,  glutaral-  
dehyde) .  Ionic strength, 0.21; 25°C.  1%, open circles; 2%, 
closed circles; 3%, open squares; 4%, dosed  squares. S.E.M. 
(n = 25). 
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FIG. 4. pH-dependent  swelling of  a lbumin-hepar in  and 
a lbumin  microspheres (1%, w/v ,  g lutara ldehyde) .  Ionic 
strength, 0.21; 25°C.  A lbumin-hepar in  microspheres,  
open circles; a lbumin  microspheres,  closed circles. S.E.M. 
(n = 25). 
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FIG. 5. Albumin-heparin and albumin microspheres 
( 1%, w/v, glutaraldehyde). Swelling dependence on ionic 
strength, pH 7.40, 25°C. Albumin-heparin microspheres, 
open circles; albumin microspheres, closed circles. S.E.M. 
(n = 25). 
thetic hydrogels has been successfully used to 
load drugs into the matrix after hydrogel 
preparation (22). This process may now be 
utilized with albumin-heparin microspheres. 
Previous investigators have shown that 
serum albumin may adsorb at the water/oil 
interface in the emulsion during the prepa- 
ration of the albumin microspheres and that 
serum albumin undergoes a change in con- 
formation so that hydrophobic regions of the 
protein are preferentially exposed to the oil 
phase (23). The formation of an adsorbed 
layer composed of denatured serum albumin 
results in marginally stable microspheres 
without heat or chemical crosslinking. The 
preferential dsorption of serum albumin, in 
the case of the albumin-heparin conjugate, 
may result in the heparin moiety being di- 
rected away from the surface of the micro- 
sphere. The properties of the albumin-heparin 
microsphere surface would then be determined 
by serum albumin. In order to ascertain the 
presence of heparin at the surface of the al- 
bumin-heparin microsphere the surfaces were 
examined using ESCA. The results of the 
ESCA studies are summarized in Table II. Al- 
bumin microspheres xhibit a preponderance 
of carbon, relative to oxygen, at the surface. 
The elemental composition of albumin-hep- 
arin microsphere surfaces was shown to be de- 
pendent on the method ofmicrosphere drying 
prior to ESCA analysis. Albumin-heparin mi- 
crospheres that had been vacuum-dried dis- 
play relative abundances of carbon, oxygen, 
and nitrogen similar to those of albumin mi- 
crospheres, uggesting that he surface contains 
largely serum albumin. When albumin-hep- 
TABLE II 
ESCA Data for Albumin-Heparin and 
Albumin Microspheres 
7 
6 
5 
q 4 
3 
2 
1 
1 2 3 4 
% (w/v) Gtutaraldehyde 
FIG. 6. Albumin-heparin microspheres' swelling in iso- 
tonic PBS, pH 7.40, 25°C. Dependence on degree of 
crosslinking. 
Binding 
energy 
Sample Element (eV) Atom % 
Albumin microspheres C(1 s) 282 71.6 
N(ls) 396 8.9 
O(ls) 528 17.4 
Na(2s) 61 1.7 
Albumin-heparin C(ls) 282 74.3 
microspheres ~ N( 1 s) 396 6.28 
O(ls) 528 16.2 
Na(2s) 61 3.17 
Albumin-heparin C(ls) 282 63.8 
microspheres b N(I s) 396 8.1 
O(ls) 528 19.9 
S(2p) 168 0.6 
Na(2s) 61 2.4 
Vaccum-dried. 
b Freeze-dried. 
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arin microspheres are freeze-dried ESCA 
analysis hows that the surface now contains 
sulfur and shows a decrease in the carbon:ox- 
ygen ratio which is consistent with the presence 
of hepafin at the surface. These results imply 
that heparin is present at the surface of mi- 
crospheres when interfaced with aqueous ys- 
tems. When the albumin-heparin micro- 
spheres are in contact with air the surfaces may 
undergo reorientation sothat serum albumin 
is largely at the surface. Such reorientation 
processes at polymer/water and polymer/air 
interfaces are well documented and occur to 
minimize interracial free energies (24). Hep- 
arin at the surface is more likely to exhibit 
bioactivity relative to heparin in the interior 
of the microsphere. 
Surface wettability was determined by con- 
tact angle measurements. Contact angles of 
albumin-heparin a d albumin gels and water 
contents of the gels are summarized in Table 
III. Both gels exhibit high water contents. The 
low contact angles are consistent with the hy- 
drated nature of the gels. The albumin-hep- 
arin gel has a slightly lower contact angle pos- 
sibly due to the immobilized hepafin at the 
surface. Contact angles are measures of gel/ 
water interfacial free energies. King et aL have 
demonstrated that the interracial free energy 
at the gel/water interface approaches zero as 
the water content of the gels approaches 30% 
(25). From these results, it may be surmised 
that the interfacial free energy approaches zero 
for both albumin-heparin a d albumin gels. 
Albumin-heparin and albumin micro- 
spheres both have a net negative surface charge 
(Table IV). Zeta potential approximates sur- 
face potential; for albumin-heparin micro- 
TABLE III 
Contact Angle Measurements and Percentage Water 
Contents of Albumin-Heparin and Albumin Hydrogels 
Hydrogel 0Cwat©r) % H20 
Albumin-heparin 10 _+ 2 a 96 
Albumin 15 _+ 3 a 68 
a SD (n ~ 3). 
MICROSPHERES 
TABLE IV 
Zeta Potentials of Albumin-Heparin and 
Albumin Microspheres 
509 
Microsphere Zeta potential (mV) 
Albumin-heparin ~ -40.0 _+ 4 c 
Albumin b - 17.0 _+ 2 c 
a Suspension medium, isotonic PBS, pH 7.40. 
b Suspension medium, 0.1% (w/v) Pluronic F-68, PBS, 
pH 7.40. 
c SD (n = 3). 
spheres the zeta potential was -40.0 mV. The 
highly negatively charged nature of the surface 
accounts for its colloidal stability in isotonic 
phosphate buffer, pH 7.40, without he pres- 
ence of surfactants and is consistent with the 
presence of heparin at the surface. The nega- 
tive surface charge may result in a decreased 
interaction with biosurfaces since most of the 
surfaces also have a net negative charge (26). 
Albumin microspheres were found to have a 
zeta potential of -17.0 mV which is in good 
agreement with the literature (10). Generally, 
polymeric microspheres require surfactants for 
colloidal stability; this may cause deleterious 
effects on drug release and affect performance 
in vivo. Surfactants may possibly be toxic and 
affect issue interactions. 
SEM micrographs (Figs. 7 and 8) taken at 
a magnification of40× and 400X ofalbumin- 
heparin microspheres suggest hat they have 
a homogeneous structure without macropores 
(27). The porosity of homogeneous hydrogels 
has been described to be related to the void 
volume between individual polymer chains 
(27). Drug release from homogeneous hydro- 
gels is expected to be slower compared to 
macroporous systems. Dry albumin-heparin 
microspheres appear spherical, have a smooth 
surface, and appear similar to albumin micro- 
spheres. 
SUMMARY 
In conclusion, the preparation ofalbumin- 
heparin microspheres has been described. It
was shown that the albumin-heparin a d al- 
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FIG. 7. SEM micrographs of albumin-heparin microspheres. Magnification: 40×, 400×. 
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FIG. 8. SEM micrographs of albumin microspheres. Magnification: 40X, 400X. 
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bumin microspheres are stimuli-sensitive hy- 
drogels characterized by a high degree of 
swelling. Albumin-heparin microspheres x- 
hibited an enhanced hydrophilicity and an in- 
creased negative charge relative to albumin 
microspheres due to the immobilized heparin. 
ESCA studies indicated that heparin is present 
at the surface of the albumin-heparin micro- 
sphere when interfaced with an aqueous ys- 
tem, but the surface may undergo reorienta- 
tion when interfaced with air, showing a pre- 
ponderance ofserum albumin. Both surfaces 
are quite wettable as evidenced by contact an- 
gle measurements. The surface of albumin- 
heparin microspheres was more negatively 
charged than that of albumin microsphere 
surfaces which resulted in greater colloidal 
stability precluding the need for the addition 
of surfactants for stabilization. In vitro bio- 
degradation, drug loading, and release of 
macromolecules from albumin-heparin mi- 
crospheres are currently being investigated. 
ACKNOWLEDGMENT 
This work was supported, in part, by TheraTech, Inc., 
Salt Lake City, Utah. 
REFERENCES 
1. Lynn, L., Davis, S. S., Illum, L., and Davis, M. C., 
Biomed. Polym. 4, 1 (1988). 
2. Tomlinson, E., J. Controlled Release 2, 385 (1985). 
3. Tomlinson, E.,Adv. Drug Delivery Rev. 1, 87 (1987). 
4. Goosen, M., Leung, Y., Chou, S., and Sun, A. M., 
Biomatter. Med. Devices Artif Organs 10, 205 
(1982). 
5. Ebert, C. D., and Kim, S. W., in "Medical Applications 
of Controlled Release" (R. S. Langer and D. L 
Wise, Eds.), p. 77. CRC Press, Boca Raton, FL, 
1984. 
6. Longo, W., and Goldberg, E., in "Methods in Enzy- 
mology" (Kenneth J. Widder and Ralph Green, 
Eds.), vol. 112, p. 18. Academic Press, New York, 
1985. 
7. Cremers, H. F. M., Feijen, J., Kwon, G., Bae, Y. H., 
Kim, S. W., Noteborn, H. P., and McVie, J. G., 
J. Controlled Release 11, 167 (1990). 
8. Hennink, W., Feijen, J., Ebert, C. D., and Kim, 
S. W., Thromb. Res. 29, 1 (1983). 
9. Smith, P. K., Mallia, A. K., and Harmanson, G., Anal. 
Biochem. 109, 466 (1980). 
10. Burger, J. J., Tomlinson, E., Mulder, E., and McVie, 
J. G., Int. J. Pharm. 23, 333 (1985). 
11. Neuberger, A., and Marshall, R. D., in "Glycoproteins: 
Their Composition, Structure and Function" (A. 
Gottschalk, Ed.), p. 190. Elsevier, Amsterdam, 
1966. 
12. Dawson, R. M., "Data for Biochemical Research," p.
474. Oxford Univ. Press, London/New York, 
1969. 
13. Peters, D. G., Hayes, J. M., and Hieftje, G. M., 
"Chemical Separations and Measurements," p. 19. 
Saunders, Philadelphia, 1974. 
14. Andrade, J. D., in "Surface and Interfacial Aspects of 
Biomedical Polymers" (J. D. Andrade, Ed.), p. 105. 
Plenum, New York, 1984. 
15. McKay, E. J., and Laurell, C. B., J. Lab. Clin. Med. 
95, 69 (1980). 
16. Rich, D. H., and Singh, J., in "The Peptides: Analysis, 
Synthesis, and Biology" (E. Gross and J. Meien- 
borer, Eds.), p. 242. Academic Press, New York, 
1979. 
17. Sokoloski, T. D., and Royer, G., in "Microspheres 
and Drug Therapy: Pharmaceutical, Immunolog- 
ical and Medical Aspects" (S. S. Davis, L. Illum, 
J. G. McVie, and E. Tomlinson, Eds.), p. 295. El- 
sevier, Amsterdam, 1984. 
18. Gupta, P. K., Hung, C. T., and Perrier, D. G., Int. J. 
Pharm. 33, 137 (1986). 
19. Rollason, G., and Sefton, M., Thromb. Res. 44, 517 
(1986). 
20. Flory, P. J., "Principles of Polymer Chemistry," p. 
584. Cornell Univ. Press, New York, 1954. 
21. Seigel, R., and Firestone, B. A., Macromolecules 21, 
3254 (1988). 
22. Hoffman, A. S., Afrassiabi, A., and Dong, L. C., J. 
Controlled Release 4, 213 ( 1986 ). 
23. Widder, K., Flouter, G., and Senyei, A., J. Pharm. 
Sci. 68, 79 (1979). 
24. Andrade, J. D., and Chert, W. Y., Surf. Interface Anal. 
8, 253 (1986). 
25. King, R. N., Andrade, J. D., Ma, S. M., Gregonis, 
D. E., and Brostrom, L R., J. Colloid Interface 
Sci. 103, 62 (1985). 
26. Norde, W., in "Microspheres and Drug Therapy: 
Pharmaceutical, Immunological nd Medical As- 
pects" (S. S. Davis, L. Illum, J. G. McVie, and E. 
Tomliuson, Eds.), p. 43. Elsevier, Amsterdam, 
1984. 
27. Ratner, B. D., in "Biocompatibility of Clinical Implant 
Material" (D. F. Williams, Ed.), p. 145. CRC Press, 
Boca Raton, FL, 1981. 
Journal of ColloM and Interface Science, Vol. 143, No. 2, May 1991 
